Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis
dc.contributor.author | Montague, E | |
dc.contributor.author | Hockenhull, Kimberley | |
dc.contributor.author | Lamarca, Angela | |
dc.contributor.author | Al-Sayed, Tamer | |
dc.contributor.author | Hubner, Richard A | |
dc.date.accessioned | 2019-10-07T15:16:41Z | |
dc.date.available | 2019-10-07T15:16:41Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Montague E, Hockenhull K, Lamarca A, Al-Sayed T, Hubner RA. Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis. BMJ Case Rep. 2019 Aug 30;12(8). | en |
dc.identifier.pmid | 31473631 | en |
dc.identifier.doi | 10.1136/bcr-2018-227987 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622190 | |
dc.description.abstract | Paraneoplastic glomerular disease is an increasingly well-recognised entity, and a wide range of both solid and haematological malignancies have been implicated. The most common glomerular disease associated with cancer is membranous nephropathy. Only a few case reports have described an association between neuroendocrine tumours (NETs) and glomerulonephritis and only one paediatric case in relation to minimal change disease. A 76-year-old woman with a well-differentiated duodenal NET presented with nephrotic syndrome and renal biopsy was suggestive of minimal change glomerulonephritis. Standard therapy with corticosteroids brought little benefit, but a dramatic improvement was seen following initiation of systemic anticancer therapy with lanreotide, a somatostatin analogue. Less than 1?month after initiation of lanreotide, the patient was no longer in a nephrotic state, and after a further 2 months of follow-up had shown no sign of relapse. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1136/bcr-2018-227987 | en |
dc.title | Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis | en |
dc.type | Article | en |
dc.contributor.department | Medical Oncology, Christie NHS Foundation Trust, Manchester, UK | en |
dc.identifier.journal | BMJ Case Reports | en |
dc.description.note | en] |